Evaluating the Cardiovascular Safety of Naltrexone/Bupropion in the United States

被引：0

作者：

Burns, Dustin ^{[1
]}

Kyle, Michael L. ^{[2
]}

Murray, Catherine Rogers ^{[1
]}

Watson, Heather ^{[1
]}

Swaney, Jeff R. ^{[1
]}

Spevack, Samuel ^{[3
]}

Leonhard, Megan ^{[1
]}

Simon, Michael A. ^{[1
]}

Moynihan, Emma

Lapane, Kate L. ^{[4
]}

Wang, Shirley V. ^{[5
]}

Longo, Craig ^{[6
]}

Ritchey, Mary E. ^{[7
]}

Dore, David ^{[1
]}

机构：

[1] Exponent Inc, Menlo Pk, CA USA

[2] Currax Pharmaceut, Brentwood, Essex, England

[3] Exponent, Menlo Pk, CA USA

[4] Consultant Exponent, Menlo Pk, CA USA

[5] Harvard Med Sch, Brigham & Womens Hosp, Div Pharmacoepidemiol & Pharmacoecon, Dept Med, Boston, MA USA

[6] APHMFP, Providence, RI USA

[7] CERobs Consulting LLC, Chapel Hill, NC USA

来源：

PHARMACOEPIDEMIOLOGY AND DRUG SAFETY | 2024年 / 33卷

关键词：

D O I：

暂无

中图分类号：

R1 [预防医学、卫生学];

学科分类号：

1004 ; 120402 ;

摘要：

540

引用

页码：224 / 224

页数：1

共 50 条

[1] Cardiovascular safety of naltrexone and bupropion
Kang, Seema
LANCET DIABETES & ENDOCRINOLOGY, 2016, 4 (05): : 390 - 390
[2] Cardiovascular safety of naltrexone and bupropion therapy: Systematic review and meta-analyses
Sposito, Andrei C.
Bonilha, Isabella
Luchiari, Beatriz
Benchimol, Alexander
Hohl, Alexandre
Moura, Fabio
Cercato, Cintia
Geloneze, Bruno
Nadruz, Wilson
Aguilar-Salinas, Carlos
Carvalho, Luiz Sergio F.
OBESITY REVIEWS, 2021, 22 (06)
[3] Use of Contrave, Naltrexone with Bupropion, Bupropion, or Naltrexone and Major Adverse Cardiovascular Events: A Systematic Literature Review
Dahlberg, Sarah
Chang, Ellen
Weiss, Sheila R.
Dopart, Pamela
Gould, Errol
Ritchey, Mary E.
DIABETES METABOLIC SYNDROME AND OBESITY, 2022, 15 : 3049 - 3067
[4] Naltrexone/bupropion: Contrave®; Naltrexone SR/bupropion SR
不详
Drugs in R & D, 2010, 10 (1) : 25 - 32
[5] Drug safety evaluation of naltrexone/bupropion for the treatment of obesity
Verpeut, Jessica L.
Bello, Nicholas T.
EXPERT OPINION ON DRUG SAFETY, 2014, 13 (06) : 831 - 841
[6] Naltrexone/Bupropion
不详
DRUGS IN R&D, 2010, 10 (01) : 25 - 32
[7] Evaluation of the Cardiovascular Risk of Naltrexone-Bupropion A Study Interrupted
Sharfstein, Joshua M.
Psaty, Bruce M.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2016, 315 (10): : 984 - 986
[8] The efficacy and safety of the naltrexone/bupropion combination for the treatment of obesity: an update
Christou, Georgios A.
Kiortsis, Dimitrios N.
HORMONES-INTERNATIONAL JOURNAL OF ENDOCRINOLOGY AND METABOLISM, 2015, 14 (03): : 370 - 375
[9] Update on drug safety evaluation of naltrexone/bupropion for the treatment of obesity
Bello, Nicholas T.
EXPERT OPINION ON DRUG SAFETY, 2019, 18 (07) : 549 - 552
[10] The efficacy and safety of the naltrexone/bupropion combination for the treatment of obesity: an update
Georgios A. Christou
Dimitrios N. Kiortsis
Hormones, 2015, 14 : 370 - 375

← 1 2 3 4 5 →